Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire de Paris:

Abstract Title:AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined with